

DMD #33639

## Characterization of human FMO3 and FMO5 expressed as maltose binding protein fusions

Robert R. Reddy<sup>1</sup>, Erik C. Ralph<sup>1</sup>, Meike S. Motika, Jun Zhang, and John R. Cashman

*Human BioMolecular Research Institute, 5310 Eastgate Mall, San Diego, CA, 92121, USA*

DMD #33639

**Running Title:**

Kinetic analysis of MBP-FMO3 and MBP-FMO5

Address correspondence to:

Dr. John R. Cashman

Human BioMolecular Research Institute

5310 Eastgate Mall

San Diego, CA 92121, USA

Tel: 858-458-9305

Fax: 858-458-9311

Email: [jcashman@hbri.org](mailto:jcashman@hbri.org)

Text-PAGE number: 22

Table number: 3

Figure number: 7

References number: 30

Abstract words: 202

Introduction words: 796

Discussion words: 913

**List of abbreviations used:**

FMO, flavin-containing monooxygenases; TMAU, trimethylaminuria; MMI, methimazole; 8-DPT, 10-[(*N,N*-dimethylaminoethyl)-2-(trifluoromethyl)]phenothiazine; DDM, *n*-dodecyl- $\beta$ -D-maltoside; MBP, maltose-binding protein; QFF, Q Fast-Flow; DC, detergent-compatible colorimetric; CHAPS, 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonic acid; DTPA, diethylenetriaminepentaacetic acid; CMC, critical micelle concentration; SEC, size exclusion chromatography.

DMD #33639

## Abstract

The flavin-containing monooxygenase (FMO) family of enzymes oxygenates nucleophilic xenobiotics and endogenous substances. Human FMO3 and FMO5 are the predominant FMO forms in adult liver. These enzymes are naturally membrane-bound, and recombinant proteins are commercially available as microsomal preparations from insect cells (i.e., Supersome FMO). Alternatively, FMO3 has previously been expressed as a soluble protein, through use of an *N*-terminal maltose binding protein (MBP) fusion. In the current study, MBP fusions of both human FMO3 and FMO5 were prepared to >90% purity in the presence of detergent, characterized for biochemical and kinetic parameters, and the parameters were compared to those of Supersome FMO samples. Although MBP-FMO enzymes afforded lower rates of turnover compared with the corresponding Supersome FMOs, both types of FMO showed identical substrate dependencies and similar responses to changes in assay conditions. Interestingly, the FMO3 enzymes showed a 2-fold activation of  $k_{cat}/K_m$  in the presence of Triton X-100. Oligomeric analysis of MBP-FMO3 also showed disassociation from a high-order oligomeric form to a monomeric status in the presence of Triton X-100. This report serves as the first direct comparison between Supersome FMOs and the corresponding MBP-fusions, and the first report of a detergent-based activation of  $k_{cat}/K_m$  that corresponds to changes in oligomerization.

DMD #33639

## Introduction

The family of flavin-containing monooxygenases (FMO) oxygenates a large variety of endogenous and exogenous substrates. FMO-catalyzed oxygenation generally produces polar and relatively stable, non-toxic products that are readily excreted from the body allowing the FMOs to play an important role in metabolic detoxication (Cashman, 2008). In the adult human liver, FMO3 and FMO5 are the predominantly expressed FMO family members (Zhang and Cashman, 2006). FMO3 is known to play a significant role in human hepatic metabolism and contributes to the metabolism of many common drugs (e.g., ranitidine, amphetamine, clozapine, tamoxifen) (for a review, see (Krueger and Williams, 2005)). Genetic mutations of *FMO3* can result in trimethylaminuria (TMAU), a metabolic disease resulting from defective trimethylamine metabolism (for a review, see (Motika et al., 2007)). In adults, *FMO5* has hepatic mRNA levels equally abundant as that of *FMO3* (Zhang and Cashman, 2006). In addition, mRNA levels for *FMO5* represent >50% of total FMO transcripts in human fetal liver and adult small intestine (Zhang and Cashman, 2006). However, mRNA levels do not always correspond to protein expression levels. One previous attempt at quantifying human hepatic FMO (Overby et al., 1997) found large variability in both the relative protein expression and mRNA levels, yielding a poor correlation between the two. In short, the contributions of FMO5 enzyme functional activity to human chemical metabolism have not been clearly established, and efforts to pursue the issue are largely impeded due to a paucity of selective functional substrates (Zhang et al., 2007).

## DMD #33639

Initial characterization of FMOs benefited largely from early work describing the purification and kinetic evaluation of pig liver FMO1 (Ziegler and Mitchell, 1972). However, ethical and technical limitations have hindered the purification of native FMO from human tissues. As FMOs are membrane associated enzymes, human FMO characterization was largely conducted with liver microsomes and S9 hepatic fractions. However, any delay between time of death and tissue preparation, as well as various practices associated with poor temperature control during tissue preparations destroy a large fraction of the FMO activity present due to its marked thermal lability (Cashman et al., 1999). Also, once hepatic microsomes are prepared, the contributions of FMO to metabolism can be difficult to distinguish from contributions associated with cytochrome P450 enzymes (CYPs) that have overlapping substrate specificities with FMOs. Although CYP activity may be easily measured by taking advantage of differences in thermal lability (i.e., heat-inactivating FMO, leaving CYPs intact), direct measurements of FMO activity are limited to the use of either specific CYP inhibitors or antibodies (Washio et al., 2001; Wang et al., 2008), or detergents such as Emulgen 911 or Lubrol that diminish CYP activity (Venkatesh et al., 1991) (Rettie et al., 1990). However, both detergents have been shown to affect FMO activity, and the presence of these detergents may complicate subsequent analysis. Due to the complications of all the above mentioned issues, there have been no publications to date showing purified and functionally active native human hepatic FMO. Therefore, recombinant FMO expression systems are of great importance for FMO-relevant research.

DMD #33639

Baculovirus-mediated recombinant expression of FMOs from insect cells was first reported in 1997 (Haining et al., 1997; Lang et al., 1998), and is arguably the most commonly utilized recombinant expression system for FMO. Insect cell microsomes containing various FMO forms are now commercially available (e.g., Supersome<sup>2</sup> FMOs from BD Gentest). Although highly useful, these enzymes are not inexpensive, are provided at relatively low enzyme concentrations (i.e., 4-10  $\mu$ M), and are not highly purified (typically in the range of 0.1 mg active FMO per mg of total protein). Alternatively, recombinant expression of FMOs from *E. coli* has also been developed using N-terminal maltose-binding-protein FMO fusions (MBP-FMO) (Brunelle et al., 1997). MBP has a well established record of increasing the solubility of proteins when utilized as an N-terminal tag (Kapust and Waugh, 1999; Fox and Waugh, 2003). The MBP fusion therefore not only serves as a “handle” for purification techniques, but increases the solubility of FMO, allowing for increased yield of highly purified FMO enzymes. Over the past decade, both Supersome FMOs and MBP-fused FMOs have been successfully used in a number of studies (e.g., characterization of FMO3 variants associated with TMAU using Supersome FMO3s (Yeung et al., 2007) or using MBP-FMO3s (Motika et al., 2009) showing the applicability of both these systems to important biological questions. However, no comparison has yet been presented for these two different systems.

In this paper, new biochemical and kinetic characterizations of MBP-FMO3 and MBP-FMO5 fusion proteins are presented, and the kinetic characteristics of MBP-FMO are compared with those of the corresponding Supersome enzymes. Although

DMD #33639

differences were observed in the apparent rates of turnover, the two enzyme systems displayed identical substrate dependencies. Interestingly, FMO3 also displayed a detergent-dependent activation of  $k_{cat}/K_m$  that corresponds to changes in the oligomeric state. Future studies may elucidate this as an important physiological means for regulating kinetic activity.

## Materials and Methods

**Reagents.** Methimazole (MMI), L-methionine, 5,5'-dithiobis(2-nitrobenzoate), glucose-6-phosphate, FAD, NADP<sup>+</sup>, NADPH, and Triton X-100 were purchased from Sigma-Aldrich Chemical Co. (St. Louis, MO). The native-PAGE sample preparation kit, 4-16% acrylamide Bis-Tris Novex gels, and Coomassie G-250 dye were purchased from Invitrogen (Life Technologies, Carlsbad, CA). Buffers and other reagents were purchased from VWR Scientific, Inc., (San Diego, CA). The synthesis of the 10-[(*N,N*-dimethylaminoethyl)-2-(trifluoromethyl)]phenothiazine (8-DPT) has been previously described (Nagata et al., 1990; Lomri et al., 1993; Zhang et al., 2003) and this product was converted to its hydrochloride salt and used as an aqueous stock solution. Supersome FMO samples (i.e., insect cell microsomal preparations of recombinant human FMO3 and FMO5) were purchased from Gentest BD Biosciences (Woburn, MA). Detergents including CHAPS, *n*-decyl- $\beta$ -D-maltoside, *n*-dodecyl- $\beta$ -D-maltoside (DDM), *n*-octyl- $\beta$ -D-glucoside, fos-choline-12, cymal-5, cymal-6, and cymal-7 were purchased from Anatrace Inc., (Maumee, OH).

**Construction of MBP-FMO Expression Vectors.** Cloning of human FMO3 and construction of the MBP-FMO3 vector was previously reported (Brunelle et al., 1997).

DMD #33639

Human *FMO5* cDNA was amplified by RT-PCR from an adult human liver cDNA library generated from total RNA isolated from a pool of human liver samples (BD Biosciences, Palo Alto, CA) using the following primers: *gatcctctagaatgactaagaaaagaattgctgtga* (*XbaI* site italicized); and *gatcctgcagccaatgaaaaacagggcagt* (*PstI* site italicized). The *FMO5* cDNA was subcloned into the expression vector pMal-c2 from New England Biolabs, (Ipswich, MA) through *XbaI* and *PstI* restriction sites to create a construct encoding an N-terminal *E. coli* maltose-binding protein (MBP) fusion of human *FMO5* similar to that previously described for human MBP-*FMO3* (Brunelle et al., 1997). The cloned *FMO5* construct used in this study matched Genebank sequence NM\_001461 except for variation P351S. Although the allelic frequency for this polymorphism position is unreported, the S351 coding sequence used in the current study was identified in Genebank sequences NT\_004434 and NM\_001144829, indicating a prominent presence in the general population.

**MBP-FMO Protein Expression and Purification.** Plasmids encoding MBP-*FMO3* or MBP-*FMO5* were transformed into *DH1 $\alpha$*  cells, and the cells were grown in SOC media for 20 h post-induction at room temperature, as previously described for MBP-*FMO3* (Motika et al., 2009). Cells were then centrifuged at 6,400g for 10 min at 4°C, and the resulting pellet was frozen at -20°C until further studies were done.

MBP-FMO proteins were purified via amylose affinity chromatography as previously described for MBP-*FMO3* (Lattard et al., 2003) with the following modifications. The desired FMO protein was eluted with comparable results using either a linear gradient (approximately 30 column volumes) of 0 to 3 mM D-maltose or a one-



## DMD #33639

step increase to 5 mM D-maltose instead of the previously reported step elution to 10 mM D-maltose. Fractions containing FMO protein were pooled and concentrated using an Amicon Ultra-15 centrifugal filter with 50 kDa molecular weight cut off (Millipore Corporation, Billerica, MA).

MBP-FMO3 was further purified via anion exchange chromatography using an ÄKTA Purifier 10 FPLC from GE Healthcare Bio-Sciences Corp. (Piscataway, NJ). Samples were loaded onto a 1 mL Q Fast-Flow (QFF) ion-exchange column (GE Healthcare Bio-Sciences Corp.) equilibrated in Buffer Q (50 mM Tris buffer, pH 7.4 containing either 0.5% CHAPS or 0.5% Triton X-100). The column was washed with 60 mM NaCl in Buffer Q (10 mL), and protein was eluted with 250 mM NaCl in Buffer Q (10 mL). The flow rate was 1 mL min<sup>-1</sup> for all wash and elution steps. Fractions containing FMO3 protein, as determined by the absorbance at 450 nm, were pooled and concentrated, as described above. Protein purity was determined with SDS-PAGE followed by Coomassie Blue staining. MBP-FMO5 was purified similarly using Buffer Q containing either 0.5% Triton X-100, 0.01% DDM, or no additional detergent.

**MBP-FMO FAD Content Determinations.** The concentration of MBP-FMO-bound FAD was determined with absorbance at 450 nm as previously described for other flavin-containing enzymes (Wagner et al., 1999) with the following modification. To remove non-specifically bound flavin from the samples, the MBP-FMO proteins were first precipitated using 20% PEG-8000 as previously described (Brunelle et al., 1997), and the supernatant was discarded. Pellet was resuspended in denaturation buffer (5 mM potassium phosphate, 25 mM KCl, 3 M guanidine hydrochloride, pH 7.5). Control

DMD #33639

incubations showed that PEG precipitation did not significantly decrease the catalytic efficiency or flavin content and recovered yields were 80-90%. Measurements showed that the enzyme-bound flavin absorbance coefficient for both FMO3 and FMO5 enzymes did not differ significantly from that of free FAD in the presence of guanidine hydrochloride ( $11,900 \text{ M}^{-1} \text{ cm}^{-1}$ ) (Wagner et al., 1999). This value was therefore used for determinations of the enzyme concentration under non-denaturing conditions.

In addition to the active enzyme (flavin-bound) concentration, the total MBP-FMO protein concentration for final purified protein was determined using the detergent-compatible colorimetric (DC) assay (Bio-Rad; Hercules, CA). MBP-FMO purified after amylose chromatography was quantified for FMO concentration using quantitative SDS-PAGE analysis as previously described (Motika et al., 2009).

**FMO3 and FMO5 Kinetic Assays.** FMO3-catalyzed S-oxygenation of MMI was monitored using the method described by Dixit and Roche (Dixit and Roche, 1984) at 37°C, as previously described (Motika et al., 2009). QFF-purified MBP-FMO3 eluted from the Q column in buffer containing 0.5% CHAPS was used for all FMO3 kinetic assays, and assays typically contained 0.2 to 0.5  $\mu\text{M}$  MBP-FMO3. Dilution of the enzyme in assay buffer yielded an assay concentration of less than 0.004% CHAPS when no additional detergent was added. This condition is referred to as the minimal detergent condition<sup>3</sup>. Alternatively, assays were also run in the presence of 0.5% CHAPS, or 0.5% Triton X-100. The substrate concentration dependence was determined over a range of 5 to 200  $\mu\text{M}$  MMI. Supersome FMO3 was assayed using the same method. Assays contained 30 to 70 nM enzyme, and were used as provided by

## DMD #33639

the manufacturer, with no additional manipulations. Observed rates of product formation were divided by the enzyme concentration as determined by the FAD absorbance (for MBP-FMO3) or as provided by the manufacturer (for Supersome FMO3), to afford units of  $\text{min}^{-1}$  (i.e.,  $\text{nmol of product} \times \text{min}^{-1} \times \text{nmol of FMO}^{-1}$ ). Plots of the rate of turnover versus the substrate concentration afforded kinetic parameters (i.e.,  $k_{\text{cat}}$ ,  $k_{\text{cat}}/K_{\text{m}}$ , and  $K_{\text{m}}$ ) by fitting the data to the Michaelis-Menten equation using GraphPad Prism version 5.01 (GraphPad Inc., San Diego, CA). Statistical comparisons of selected data fittings were done using the extra sum of squares F-test provided in the GraphPad Prism software. The stability of MBP-FMO3 under the above standard assay conditions was determined by incubating 60  $\mu\text{g}$  of protein in the presence of NADPH at 37°C for time intervals ranging from 5 to 30 min, and then assessing the S-oxygenation activity with 80  $\mu\text{M}$  MMI.

For detergent  $EC_{50}$  value evaluations, varied concentrations of Triton X-100 or CHAPS were added to the minimal detergent assay condition described above. These assays were run in the presence of 5  $\mu\text{M}$  MMI, and turnover was initiated by the addition of 0.5  $\mu\text{M}$  MBP-FMO3.

In addition to MMI, oxygenation activity of MBP-FMO3 was also characterized with L-Met as a substrate. S-Oxygenation of L-Met was monitored photometrically by following NADPH consumption at 340 nm, as previously described for MBP-FMO3 catalyzed N-oxygenation of trimethylamine (Motika et al., 2009). Assays were run at 37 °C pH 8.5, under minimal detergent conditions and in the presence of 0.5% CHAPS, or 0.5% Triton X-100. The concentration-dependence was determined over a range of

DMD #33639

0.25 to 50 mM L-Met, and kinetic parameters were obtained from the Michaelis-Menten equation, as described above. Assays contained 0.2 to 2  $\mu$ M MBP-FMO3. Supersome FMO3 activity was also measured with this assay in the presence of 50 mM methionine and 0.1 to 0.4  $\mu$ M enzyme.

FMO5-catalyzed *N*-oxygenation of 8-DPT HCl at 37°C pH 8.5 was monitored with an HPLC-based assay previously described (Zhang et al., 2007). This assay was used for both MBP-FMO5 and Supersome FMO5, and assays contained approximately 0.2  $\mu$ M FMO5. The rate of 8-DPT N-oxide product formation was initially assessed at 400  $\mu$ M 8-DPT, and found to be a linear function of time over a range of 0 to 30 min. Subsequent assays utilized a 20 min incubation time. The substrate concentration dependence was determined over a range of 10  $\mu$ M to 2 mM 8-DPT, and kinetic parameters were obtained by fitting the data to the Michaelis-Menten equation as described above.

**Oligomeric Analysis.** The oligomeric state of the purified MBP-FMO proteins was analyzed using non-denaturing (native)-PAGE and size exclusion chromatography (SEC) methods. For native-PAGE analysis, purified MBP-FMO samples (approximately 6  $\mu$ g) were prepared in loading buffer using the NativePAGE Sample Prep kit (Life Science Technologies, San Diego, CA), according to the manufacturer's instructions, and gels were run at 150 volts for 2.5 h. After destaining in 40% methanol and 10% acetic acid, the Coomassie dye yielded a limit of detection of approximately 60 ng, and no additional staining was needed. Conalbumin (75 kDa), aldolase (158 kDa), ferritin (445 kDa), and thyroglobulin, (669 kDa) (GE Healthcare Bio-Sciences Corp) were used

DMD #33639

as molecular weight standards. The electrophoretic mobilities of samples were visually compared to those of the molecular weight standards listed above.

Native-PAGE analysis was also used to assess the oligomeric state of FMO after removal of the MBP moiety using Factor Xa (New England Biolabs, Ipswich, MA). MBP-FMO5 (4.5 mg/mL) was first incubated with 0.1 mg/mL of Factor Xa at 37°C for 2 h in 50 mM Tris, 150 mM KCl, pH 7.4, with 2 mM CaCl<sub>2</sub> and 0.5 mM NADPH. Samples were then prepared for electrophoresis by diluting the enzyme into the desired detergent condition (i.e., 0 or 0.5% Triton X-100) and were analyzed as described above. Surprisingly, FMO5 protein bands consistently showed lower staining intensity per protein mass under native conditions after Factor Xa treatment, relative to MBP-FMO5. Therefore, larger protein amounts (19 µg) were utilized in this analysis.

Analytical SEC was done using a Superose 6 10/300 GL column from GE Healthcare Bio-Sciences Corp. The column was equilibrated and run in Buffer S (50 mM Tris pH 7.4, 150 mM NaCl), with either 0.5% CHAPS or 0.5% Triton X-100 for MBP-FMO3, and 0.5% Triton X-100, 0.01% DDM, or no added detergent for MBP-FMO5. Protein samples (0.2 mg; 100 µL) were run with a flow-rate of 0.5 mL min<sup>-1</sup>, and elution volumes were compared to those of molecular weight standards (listed above) run under identical conditions.

DMD #33639

## Results

### **Expression and Purification of Recombinant MBP-FMO3 and MBP-FMO5.**

Purification of MBP-FMO3 using amylose affinity chromatography has been previously reported in the literature (Brunelle et al., 1997), and purification of MBP-FMO5 yielded comparable results using this method. Additional purification using anion-exchange chromatography (i.e., QFF) was optimized for both MBP-FMO3 and MBP-FMO5. Protein yields following ion-exchange chromatography, as determined by the DC assay, were approximately 2-4 mg per liter of bacterial culture for MBP-FMO3 and 5-10 mg per liter for MBP-FMO5. SDS-PAGE analysis of the QFF-purified MBP-FMO samples showed a major band of approximately 100 kDa (Fig. 1). This is in agreement with the calculated molecular weight of 102 kDa for MBP-FMO3 and 104 kDa for MBP-FMO5 based on primary sequences. Coomassie blue staining of highly purified MBP-FMO enzymes (i.e., 4  $\mu$ g from QFF chromatography, Fig. 1) on SDS-PAGE indicated greater than 90% purity.

**MBP-FMO FAD Content Determination.** Both purified MBP-FMO3 and MBP-FMO5 exhibited a distinctive yellow color, and elution peaks monitored for FAD at 450 nm correlated with FMO selective functional activity, indicating co-purification of FAD with the MBP-FMO enzymes. The FAD concentration determined by absorbance at 450 nm was compared to the total MBP-FMO protein concentrations determined with a DC assay. The molar ratio of FAD to MBP-FMO3 varied from 0.5 to 0.9 with three independent enzyme preparations. However, the enzyme functional activity of these enzyme preparations showed good reproducibility under saturating substrate

DMD #33639

concentrations (i.e.,  $k_{\text{cat}}$  (mean  $\pm$  SD) =  $8 \pm 2 \text{ min}^{-1}$ ), when the values were normalized by the active enzyme concentration as determined by the FAD content. The FAD content of MBP-FMO5 was reproducible with molar ratios of 0.6 and 0.7 from two independent enzyme preparations. Because only FMO enzymes containing bound FAD is catalytically active, experimentally determined FAD content values for MBP-FMOs and vendor provided FAD content values for Supersome FMOs were used to define active enzyme concentration.

**MBP-FMO3 and MBP-FMO5 Thermal Stability.** Human FMO3 is a thermally labile enzyme (Cashman et al., 1999), and MBP-FMO3 will rapidly inactivate at 40°C in the absence of NADPH (Motika et al., 2009). Similar instability has been reported for mouse MBP-FMO5 in the absence of NADPH (Zhang et al., 2007), although human FMO5 has not been previously studied. It was therefore essential to assess the thermal stability of the MBP-FMO enzymes under the standard assay conditions. As shown in Fig. 2, MBP-FMO3 showed less than 18% loss of MMI S-oxygenation activity over a 30 min period at 37°C in the presence of NADPH. In a slightly different analysis, human MBP-FMO5 showed 8-DPT N-oxide formation with linear time dependence over a 30 min incubation period at 37°C in the presence of NADPH (Fig. 3). A time-dependent loss of activity would have caused deviation from linearity. The results clearly indicated sufficient thermal stability for both enzymes under the standard assay conditions for subsequent kinetic analysis.

**Kinetic Evaluation of Purified MBP-FMO and Supersome FMO.** Steady-state kinetic parameters (i.e.,  $k_{\text{cat}}$ ,  $K_m$ , and  $k_{\text{cat}}/K_m$ ) were determined with highly purified MBP-

## DMD #33639

FMO3 in the presence of different detergent conditions (Table 1). In the presence of minimal detergent conditions,  $k_{\text{cat}}$  and  $K_m$  were  $10.8 \text{ min}^{-1}$  and  $32 \text{ }\mu\text{M}$ , respectively, for MBP-FMO3-mediated S-oxygenation of MMI. Comparable  $K_m$  and  $k_{\text{cat}}$  values were obtained for MBP-FMO3 in the presence of 0.5% CHAPS. However, in the presence of 0.5% Triton X-100, a 2-fold increase in  $k_{\text{cat}}/K_m$  ( $p < 1 \times 10^{-4}$ ) was observed. A similar detergent effect was also observed for S-oxygenation of L-Met (Table 2). The presence of Triton X-100 decreased the apparent  $K_m$  value from 6.5 to 4.1 mM while modestly increasing  $k_{\text{cat}}$ , yielding a 2-fold increase in  $k_{\text{cat}}/K_m$  ( $p = 1.3 \times 10^{-3}$ ).

Commercially available Supersome FMO3 was assayed under the same conditions as MBP-FMO3. The apparent  $K_m$  value for MMI oxygenation was in excellent agreement with the value obtained for MBP-FMO3 (Table 1). Similarly, a L-Met  $K_m$  value of 6.5 mM has been previously reported for Supersome FMO3 purchased from the same manufacturer (Elfarra and Krause, 2005), in agreement with the value determined for the MBP-FMO enzyme (Table 2). In contrast to the  $K_m$  values, the  $k_{\text{cat}}$  (and  $k_{\text{cat}}/K_m$ ) values obtained for Supersome FMO3 catalyzed oxygenations were approximately 3 to 5-fold greater than those observed for the MBP-FMO enzyme. Supersome FMO3  $k_{\text{cat}}$  values of 33 and  $45 \text{ min}^{-1}$  were observed in minimal detergent conditions for MMI and L-Met, respectively. These values are in good agreement with the reported  $k_{\text{cat}}$  value of  $34 \text{ min}^{-1}$  with methyl *p*-toyl sulfide (Haining et al., 1997).

Interestingly, Supersome FMO3 oxygenase activity was enhanced to a similar degree as that observed for MBP-FMO3 by addition of 0.5% Triton X-100. Both enzymes showed a modest increase in  $k_{\text{cat}}$  values (1.2 to 1.3-fold) and a more



DMD #33639

significant increase in  $k_{\text{cat}}/K_m$  values (1.8-fold,  $p < 1 \times 10^{-3}$  for Supersome FMO3 and 2.5-fold,  $p < 1 \times 10^{-4}$  for the MBP-fusion enzyme). A similar  $k_{\text{cat}}$  effect (1.2-fold) has also been reported for native mouse-liver FMO preparations using thiourea oxygenation (Venkatesh et al., 1991). The Triton X-100-dependent increase in  $k_{\text{cat}}/K_m$  was sufficient to determine an  $EC_{50}$  value for activation of MBP-FMO3 in 5  $\mu\text{M}$  MMI. The data showed fit to a sigmoidal dose-response, with a two-fold increase in activity, and an  $EC_{50}$  value of  $57 \pm 10 \mu\text{M}$  (Fig. 4), or approximately 36 ppm (using an average molecular weight value of 625 Da). This value is significantly smaller than the CMC range of 0.2-0.9 mM reported by the manufacturer, and suggests that the activation may not require micelle formation. In contrast, CHAPS did not increase the rate of MMI oxygenation at concentrations below the reported CMC value of 7-8 mM, but did show activation at higher concentrations, with a predicted  $EC_{50}$  value above 60 mM (Fig.4)<sup>4</sup>.

Kinetic parameters for 8-DPT *N*-oxygenation in the presence of MBP-FMO5 and Supersome FMO5 were also compared (Table 3). As seen for the FMO3 enzymes, MBP-FMO5 and Supersome FMO5 showed identical  $K_m$  values, while the Supersome FMO had increased  $k_{\text{cat}}$  and  $k_{\text{cat}}/K_m$  values (1.7-fold, Table 3). The Supersome  $k_{\text{cat}}$  value of  $1.0 \text{ min}^{-1}$  is in reasonable agreement with the  $k_{\text{cat}}$  value of  $1.4 \text{ min}^{-1}$  for methyl *p*-tolyl sulfide supplied by the manufacturer. The difference may be attributable to the difference in assay conditions (i.e., pH 8.5 vs. pH 9.5).

**Oligomeric Analysis of Purified MBP-FMO proteins.** Native-PAGE analysis was done utilizing different detergent conditions in the sample loading buffer. Triton X-100-solubilized MBP-FMO enzymes indicated the presence of monomers and

## DMD #33639

oligomerized proteins that were interpreted as dimers and hexamers for MBP-FMO3, and as monomers, dimers, tetramers, and hexamers for MBP-FMO5 (Figs. 5 and 6). In contrast, MBP-FMOs solubilized with other detergents tested (i.e., MBP-FMO3 solubilized in 0.5% CHAPS, and MBP-FMO5 solubilized in 0.01% DDM), or minimal detergent conditions, contained hexameric and larger aggregates of protein. Conceptually identical trends with regards to oligomeric organization were seen with MBP-FMO5 after cleavage of the MBP-moiety via treatment with Factor Xa (Fig. 6), indicating that the oligomerization was not dependent on the MBP-moiety. Furthermore, the addition or removal of respective detergents changed the nature of the oligomeric state, indicating that the oligomeric states for MBP-FMOs were reversible (data not shown).

In native-PAGE analysis, the detergents used to solubilize proteins were included in the loading buffer, but became displaced by the Coomassie blue G-250 present in the running buffer during electrophoresis. In contrast, SEC has the benefit of maintaining a constant detergent concentration throughout the analysis. Therefore, MBP-FMO3 was further analyzed using SEC. When 0.5% Triton X-100 was present in the running buffer, a single peak of MBP-FMO3 eluted at 16.8 mL (Fig. 7A). This value was between the elution volumes for the 75 and 150 kDa protein standards run under the same conditions, consistent with a monomeric form of the enzyme. When 0.5% CHAPS was present in the running buffer for MBP-FMO3, a single peak eluted at 12.7 mL (Fig. 7B). This value is most comparable to the elution volume of the 669 kDa protein standard (12.9 mL) run under identical conditions, and is consistent with a hexameric or higher

DMD #33639

order MBP-FMO3 protein. Thus, the SEC analysis supported the detergent-dependent shift in oligomeric states observed in the native-PAGE analysis.

DMD #33639

## Discussion

In this study, recombinant human FMO3 and FMO5 were expressed as fusion proteins with an N-terminal MBP moiety and purified from *E. coli*. The enzymes' steady-state kinetic parameters were determined and compared to those obtained from commercially available Supersome (i.e., membrane associated) FMO enzymes. Interestingly, both Supersome and MBP-fused FMOs showed kinetic activation in the presence of Triton X-100. Oligomeric analysis of MBP-FMO also showed oligomeric disassociation in the presence of Triton X-100, suggesting a possible relationship between the oligomeric state and kinetic activation.

Purification of MBP-FMO3 and MBP-FMO5 involved a straightforward two-step amylose affinity and anion-exchange chromatography, with levels of protein yield in good agreement with expected yields for MBP-fusions expressed in *E. coli* (Pattenden and Thomas, 2008). The FAD content for the final purified MBP-FMO3 and MBP-FMO5 (65-75%, molar ratio), were comparable to values reported for the Supersome FMO3 (i.e., 40-50% (Haining et al., 1997; Yeung et al., 2007)), suggesting that proper protein folding and co-factor association during expression were not grossly disrupted by the MBP-fusion or subsequent purification procedures.

Kinetic studies showed that the recombinant MBP-FMO enzymes and Supersome FMOs behave very similarly. Under minimal detergent assay conditions, the MBP-FMO3 and MBP-FMO5  $K_m$  values for their respective substrates were identical within experimental error to their Supersome counterparts. However, both Supersome FMO3 and Supersome FMO5 showed greater  $k_{cat}$  and  $k_{cat}/K_m$  values compared with

## DMD #33639

their corresponding MBP-FMOs. Unlike the  $K_m$  values, the apparent  $k_{cat}$  and  $k_{cat}/K_m$  are dependent upon the apparent active enzyme concentration (i.e., as measured by FAD content). Therefore, the FAD contents for both Supersome and MBP-FMO3 were confirmed using an HPLC method (as described in Lang et al., 1998, data not shown). The observed differences in FMO activity were not attributable to differences in FAD quantification. Instead, the results suggest some fraction of the MBP-fusion FMO enzyme remains inactive, despite retaining the ability to bind FAD. Furthermore, cleavage of the MBP moiety does not yield an increase in catalytic activity, thereby ruling out a simple steric hindrance to the active site or other reversible phenomenon resulting from MBP-FMO fusion<sup>5</sup>.

Interestingly, during the course of kinetic characterization, an approximately 2-fold activation of  $k_{cat}/K_m$  and  $K_m$  values were observed for both MBP-FMO3 and Supersome FMO3. The similar increase seen with both Supersome and MBP-enzymes indicates that this phenomenon was not an artifact of the MBP-fusion. The observed  $EC_{50}$  value determined with MBP-FMO3 was well below the CMC value, suggesting that Triton X-100 association with MBP-FMO involved a limited number of Triton X-100 molecules interacting with specific hydrophobic protein regions, rather than general micelle formation.

Although previous studies have noted detergent effects on  $k_{cat}$  values for mammalian FMO enzymes, this is the first report of detergent-mediated activation of the bimolecular rate constant  $k_{cat}/K_m$  for these enzymes<sup>6</sup>. As FMO substrates do not form a Michaelis-complex with the enzyme (Poulsen and Ziegler, 1995), the  $k_{cat}/K_m$  parameter

## DMD #33639

reflects the rate of productive collision of substrate with the 4a-hydroperoxyflavin. The increased activity therefore suggests greater access of the substrate to the active site in the presence of Triton X-100.

In addition to the kinetic analyses, MBP-FMOs were analyzed for their oligomeric status. Although poorly characterized in the literature, data suggests mammalian FMO's are present in higher-order oligomers. Pig liver FMO1 has been described as a higher-order oligomer (Ziegler and Mitchell, 1972), with one report of tetramers and octamers<sup>7</sup> although no experimental results have been published. Similarly, rabbit FMO2 was reported as "aggregated" under native-PAGE conditions (Krueger et al.), with a detergent-dependent dissociation to a dimeric state using a truncated variant. To date, there is no detailed oligomeric analysis of native human FMO enzymes. The current study found high-order oligomers for both recombinant MBP-FMO3 and MBP-FMO5 that were interpreted as hexamers. Interestingly, these oligomers disassociated in the presence of Triton X-100. A conceptually identical detergent-dependent oligomeric disassociation was observed after proteolytic removal of the MBP-moiety from MBP-FMO5, suggesting the oligomeric states are attributable to the FMO-moieties and not an artifact of the MBP-fusions. Characterization of the Supersome enzymes utilizing these simple methods was prohibited by the relatively low purity and FMO concentration of commercially available enzyme.

Although further studies will be required to fully elucidate the mechanism of Triton X-100 dependent FMO activation, it is intriguing to note that the kinetic activation correlated with the oligomeric disassociation induced by Triton X-100, suggesting that

## DMD #33639

the two phenomena may be functionally related. Furthermore, a physiological mechanism of kinetic regulation based on oligomeric disassociation to improve substrate access to the enzyme active site, although purely speculative for FMOs at present, is not inconsistent with these results.

In conclusion, this study provides the only direct comparison between human MBP-FMO fusion proteins and their Supersome counterparts, and is the first report of detergent-based kinetic activation of  $k_{\text{cat}}/K_m$  with a corresponding detergent-based oligomeric disassociation. MBP-fused and Supersome FMO have different apparent rates of turnover, and this may affect certain studies when absolute kinetic values are important. However, for many studies when relative values are highly informative (e.g., when comparing the rates of one substrate to another, or the rate of a wild-type enzyme to that of a variant), MBP-FMO has shown to be useful (e.g., Motika et al., 2009). Furthermore, the MBP-FMO system provides more enzyme, higher levels of purity, and simpler purification schemes in comparison with Supersome FMO. These factors combine into significant advantages that show the utility of the MBP-FMO fusion proteins especially for biochemical characterizations in which protein purity is critical. This report suggests that the MBP-FMO fusion expression system is a robust and useful alternative approach to generate high quality recombinant FMO enzymes.

DMD #33639

## **Acknowledgments**

We thank HBRI scientists Dr. Karl Okolotowicz for chemical synthesis of 8-DPT HCl and Dr. Xueying Zheng for HPLC assays.



DMD #33639

## References

- Brunelle A, Bi YA, Lin J, Russell B, Luy L, Berkman C, and Cashman J (1997) Characterization of two human flavin-containing monooxygenase (form 3) enzymes expressed in *Escherichia coli* as maltose binding protein fusions. *Drug Metab Dispos* **25**:1001-1007.
- Cashman JR (2008) Role of flavin-containing monooxygenase in drug development. *Expert Opin Drug Met* **4**:1507-1521.
- Cashman JR, Xiong YN, Xu L, and Janowsky A (1999) N-oxygenation of amphetamine and methamphetamine by the human flavin-containing monooxygenase (form 3): role in bioactivation and detoxication. *J Pharmacol Exp Ther* **288**:1251-1260.
- Dixit A and Roche TE (1984) Spectrophotometric assay of the flavin-containing monooxygenase and changes in its activity in female mouse liver with nutritional and diurnal conditions. *Arch Biochem Biophys* **233**:50-63.
- Elfarra AA and Krause RJ (2005) Potential roles of flavin-containing monooxygenases in sulfoxidation reactions of L-methionine, N-acetyl-L-methionine and peptides containing L-methionine. *Biochim Biophys Acta* **1703**:183-189.
- Fox JD and Waugh DS (2003) Maltose-binding protein as a solubility enhancer. *Methods Mol Biol* **205**:99-117.
- Haining RL, Hunter AP, Sadeque AJ, Philpot RM, and Rettie AE (1997) Baculovirus-mediated expression and purification of human FMO3: catalytic, immunochemical, and structural characterization. *Drug Metab Dispos* **25**:790-797.

DMD #33639

Kapust RB and Waugh DS (1999) Escherichia coli maltose-binding protein is uncommonly effective at promoting the solubility of polypeptides to which it is fused. *Protein Sci* **8**:1668-1674.

Krueger SK, Siddens LK, Henderson MC, VanDyke JE, Karplus PA, Pereira CB, and Williams DE (2006) C-Terminal truncation of rabbit flavin-containing monooxygenase isoform 2 enhances solubility. *Arch Biochem Biophys* **450**:149-156.

Krueger SK and Williams DE (2005) Mammalian flavin-containing monooxygenases: structure/function, genetic polymorphisms and role in drug metabolism. *Pharmacol Ther* **106**:357-387.

Lang DH, Yeung CK, Peter RM, Ibarra C, Gasser R, Itagaki K, Philpot RM, and Rettie AE (1998) Isoform specificity of trimethylamine N-oxygenation by human flavin-containing monooxygenase (FMO) and P450 enzymes: selective catalysis by FMO3. *Biochem Pharmacol* **56**:1005-1012.

Lattard V, Zhang J, Tran Q, Furnes B, Schlenk D, and Cashman JR (2003) Two new polymorphisms of the FMO3 gene in Caucasian and African-American populations: comparative genetic and functional studies. *Drug Metab Dispos* **31**:854-860.

Lomri N, Thomas J, and Cashman JR (1993) Expression in Escherichia coli of the cloned flavin-containing monooxygenase from pig liver. *J Biol Chem* **268**:5048-5054.

DMD #33639

Motika MS, Zhang J, and Cashman JR (2007) Flavin-containing monooxygenase 3 and human disease. *Expert Opin Drug Metab Toxicol* **3**:831-845.

Motika MS, Zhang J, Zheng X, Riedler K, and Cashman JR (2009) Novel variants of the human flavin-containing monooxygenase 3 (FMO3) gene associated with trimethylaminuria. *Mol Genet Metab*.

Nagata T, Williams DE, and Ziegler DM (1990) Substrate specificities of rabbit lung and porcine liver flavin-containing monooxygenases: differences due to substrate size. *Chem Res Toxicol* **3**:372-376.

Overby LH, Carver GC, and Philpot RM (1997) Quantitation and kinetic properties of hepatic microsomal and recombinant flavin-containing monooxygenases 3 and 5 from humans. *Chem Biol Interact* **106**:29-45.

Palfey BA and McDonald CA (2010) Control of catalysis in flavin-dependent monooxygenases. *Arch Biochem Biophys* **493**:26-36.

Pattenden LK and Thomas WG (2008) Amylose affinity chromatography of maltose-binding protein: purification by both native and novel matrix-assisted dialysis refolding methods. *Methods Mol Biol* **421**:169-189.

Poulsen LL and Ziegler DM (1995) Multisubstrate flavin-containing monooxygenases: applications of mechanism to specificity. *Chem Biol Interact* **96**:57-73.

Rettie AE, Bogucki BD, Lim I, and Meier GP (1990) Stereoselective sulfoxidation of a series of alkyl p-tolyl sulfides by microsomal and purified flavin-containing monooxygenases. *Mol Pharmacol* **37**:643-651.

DMD #33639

- Venkatesh K, Levi PE, and Hodgson E (1991) The effect of detergents on the purified flavin-containing monooxygenase of mouse-liver, kidney and lungs. *General Pharmacology* **22**:549-552.
- Wagner MA, Khanna P, and Jorns MS (1999) Structure of the flavocoenzyme of two homologous amine oxidases: monomeric sarcosine oxidase and N-methyltryptophan oxidase. *Biochemistry* **38**:5588-5595.
- Wang LF, Christopher LJ, Cui DH, Li WY, Iyer R, Humphreys WG, and Zhang DL (2008) Identification of the human enzymes involved in the oxidative metabolism of dasatinib: An effective approach for determining metabolite formation kinetics. *Drug Metab Dispos* **36**:1828-1839.
- Washio T, Arisawa H, Kohsaka K, and Yasuda H (2001) Identification of human drug-metabolizing enzymes involved in the metabolism of SNI-2011. *Biol Pharm Bull* **24**:1263-1266.
- Yeung CK, Adman ET, and Rettie AE (2007) Functional characterization of genetic variants of human FMO3 associated with trimethylaminuria. *Arch Biochem Biophys* **464**:251-259.
- Zhang J and Cashman JR (2006) Quantitative analysis of FMO gene mRNA levels in human tissues. *Drug Metab Dispos* **34**:19-26.
- Zhang J, Cerny MA, Lawson M, Mosadeghi R, and Cashman JR (2007) Functional activity of the mouse flavin-containing monooxygenase forms 1, 3, and 5. *J Biochem Mol Toxicol* **21**:206-215.

DMD #33639

Zhang J, Tran Q, Lattard V, and Cashman JR (2003) Deleterious mutations in the flavin-containing monooxygenase 3 (FMO3) gene causing trimethylaminuria. *Pharmacogenetics* **13**:495-500.

Ziegler DM and Mitchell CH (1972) Microsomal oxidase. 4. Properties of a mixed-function amine oxidase isolated from pig liver-microsomes. *Arch Biochem Biophys* **150**:116-125.

DMD #33639

## Footnotes

This work was supported by National Institute of Health grant [DK59618].

Address correspondence to John R. Cashman, Human BioMolecular Research Institute, San Diego, California, 92121-2804.

<sup>1</sup>R.R.R. and E.C.R. contributed equally to this work.

<sup>2</sup>The term Supersome FMO is utilized throughout the manuscript to refer to any microsomal preparation of human FMO enzymes from insect cells, whether or not said preparations were purchased from a commercial source.

<sup>3</sup>This calculation assumes the CHAPS buffer passed freely through the 50 kDa filter during the enzyme concentration steps described in the Materials and Methods, and was not itself concentrated.

<sup>4</sup>The  $EC_{50}$  value for CHAPS was predicted by fitting the data to a sigmoidal dose-response with a fixed upper limit equal to that observed in the Triton X-100-dependent trend. The reported value is the lower limit from the resulting 90% confidence interval.

<sup>5</sup>MBP-FMO5 relative activity was  $97\% \pm 17\%$  after 3 h incubation with Factor Xa compared to the same incubation time in the absence of Factor Xa. MBP-FMO3 cleavage previously yielded 112% relative activity, as reported by (Brunelle et al., 1997).

<sup>6</sup>In a previous study (Brunelle et al., 1997), MBP-FMO3 phenothiazine *N*-oxygenation decreased at Triton X-100 concentrations above 0.05%. This is attributed to the hydrophobic nature of the phenothiazine substrates leading to a detergent interference with the specific assay. A similar situation was reported for decreased mouse-liver FMO oxygenation of phorate in 1% Triton X-100 (Venkatesh et al., 1991).

DMD #33639

<sup>7</sup>In a very recent review, Palfey and McDonald (Palfey and McDonald, 2010) reported pig liver FMO1 purifies as a tetramer or octamer with bound lipid. However, no primary data or literature reference was cited.

DMD #33639

## Figure Legends

**Figure 1. SDS-PAGE analysis of MBP-FMO3 (lane 2) and MBP-FMO5 (lane 3).** QFF purified MBP-FMO samples (4  $\mu$ g) were analyzed for molecular weight and purity by SDS-PAGE analysis. The numeric values indicate the molecular weights (kDa) for the protein standards shown in lane 1.

**Figure 2. Time-dependent thermal stability of MBP-FMO3.** MBP-FMO3 was incubated at 37°C in the absence (●) or presence of 0.5% Triton X-100 (□) or 0.5% CHAPS (▲). After various incubation periods, catalytic turnover was determined by the addition of MMI and the resultant S-oxygenation was measured as described in the Materials and Methods. The figure shows the ratio of the observed activity at the indicated incubation times ( $v_t$ ) relative to the activity prior to incubation at 37°C ( $v_0$ ). Data points represent the average of duplicated data points.

**Figure 3. Time-dependent thermal stability of FMO5.** Supersomal (▲) or MBP-FMO5 (●) was incubated at 37°C in the absence of detergent, with a starting concentration of 400  $\mu$ M 8-DPT. The incubations were allowed to progress for various time periods, and then assessed for 8-DPT N-oxide formation, as described in the Materials and Methods. Values were normalized for the enzyme concentrations. The lines show the fit of the data to a constant rate of catalysis over the 30 min time period. Data markers represent



DMD #33639

the average of duplicated data points. The standard deviations are smaller than the data markers.

**Figure 4. Triton X-100 (●) and CHAPS (▲) activation of MBP-FMO3 S-oxygenation of MMI.** Assays were run at 37°C, pH 8.5, as previously described. Incubations contained 5  $\mu$ M MMI and 0.5  $\mu$ M MBP-FMO3. Observed rates of catalysis were divided by the activity observed under minimal detergent conditions (indicated by the data points on the Y axis), and the data were fit to a sigmoidal dose-response curve.

**Figure 5. Native-PAGE analysis of MBP-FMO3 and MBP-FMO5.** Approximately 6  $\mu$ g of MBP-FMO3 (lanes 2 and 3) or MBP-FMO5 (lanes 4-6) were solubilized with or without detergents and run on separate native-PAGE gels. The mobilities of the proteins were compared to that of molecular weight standards (lanes 1 and 7) with the indicated masses (kDa). The detergent conditions for MBP-FMO3 were as follows: lane 2, 0.5% Triton X-100; lane 3, 0.5% CHAPS. The detergent conditions for MBP-FMO5 were as follows: lane 4, 0.5% Triton X-100; lane 5, 0.01% DDM; lane 6, minimal detergent. Asterisks (lanes 2 and 4) or brackets (lanes 3, 5, and 6) were placed to the right of the indicated lanes to highlight FMO protein bands.

**Figure 6. Native-PAGE analysis of untreated and Factor Xa-treated MBP-FMO5.**

Untreated (lanes 2 and 3) and Factor Xa-treated MBP-FMO5 (lanes 4 and 5), were prepared in minimal detergent (lanes 2 and 4) or 0.5% triton X-100 (lanes 3 and 5) and

DMD #33639

analyzed via native-PAGE. The mobilities of the proteins were compared to that of molecular weight standards (lanes 1) with the indicated masses (kDa). For lanes 4 and 5, regions showing FMO protein are indicated with brackets, while MBP released from the fusion protein is indicated with an asterisk.

**Figure 7. Size exclusion chromatography elution profiles of MBP-FMO3.** A Superose 6 10/300 GL column was equilibrated in 50 mM Tris pH 7.4, 150 mM NaCl, with either (A) 0.5% Triton X-100 or (B) 0.5% CHAPS. Protein (200  $\mu$ g) was applied to the column and eluted with the respective equilibration buffer at 0.5 mL min<sup>-1</sup> flow rate. The elution of MBP-FMO3 was monitored at 450 nm based on FAD absorbance.

DMD #33639

**Table 1.** Steady-state kinetic parameters for FMO3 catalyzed S-oxygenation of MMI.

Enzyme	Detergent <sup>a</sup>	$k_{cat}$ , min <sup>-1</sup>	$K_m$ , μM	$k_{cat}/K_m$ , min <sup>-1</sup> μM <sup>-1</sup>
MBP-FMO3	Minimal detergent	10.8 ± 0.2	32 ± 2	0.34 ± 0.01
	CHAPS	11.5 ± 0.4	38 ± 3	0.30 ± 0.02
	Triton X-100	13.3 ± 0.7	15 ± 2	0.86 ± 0.07 <sup>b</sup>
Supersomal FMO3	Minimal detergent	33 ± 0.3	35 ± 2 <sup>c</sup>	0.91 ± 0.07
	CHAPS	40 ± 2 <sup>c</sup>	ND <sup>d</sup>	ND
	Triton X-100	43 ± 6 <sup>c</sup>	25 ± 3 <sup>c</sup>	1.6 ± 0.1 <sup>c,e</sup>

Kinetic assays were done at 37 °C, pH 8.5. <sup>a</sup>When present, detergent concentrations were 0.5% (w/v). Unless otherwise indicated, values are the fitting value and error from a single determination. <sup>b</sup>Comparison of this value to that obtained with minimal detergent conditions yielded  $p < 1 \times 10^{-4}$ . <sup>c</sup>Indicated values are the average and standard deviation of 2 or more independent determinations. When present, detergent concentrations were 0.5% (w/v). <sup>d</sup>ND indicates values were not determined. <sup>e</sup>Comparison of this value to that obtained with minimal detergent conditions yielded  $p < 1 \times 10^{-3}$ .

DMD #33639

**Table 2.** Steady-state kinetic parameters for FMO3 catalyzed oxygenation of methionine.

Enzyme	Detergent <sup>a</sup>	$k_{cat}$ , min <sup>-1</sup>	$K_m$ , mM	$k_{cat}/K_m$ , min <sup>-1</sup> mM <sup>-1</sup>
MBP-FMO3	Minimal detergent	7.0 ± 0.3	6.5 ± 0.8	1.1 ± 0.2
	CHAPS	8.6 ± 0.2	5.5 ± 0.5	1.6 ± 0.1
	Triton X-100	8.5 ± 0.2	4.1 ± 0.3	2.1 ± 0.2 <sup>b</sup>
Supersomal FMO3	Minimal detergent	45 <sup>c</sup>	ND <sup>e</sup>	ND
	Triton X-100	47 ± 3 <sup>d</sup>	ND	ND

Kinetic assays were done at 37 °C, pH 8.5. <sup>a</sup>When present, detergent concentrations were 0.5% (w/v). Unless otherwise indicated, values are the fitting value and error from a single determination. <sup>b</sup>Comparison of this value to that obtained with minimal detergent conditions yielded  $p = 1.3 \times 10^{-3}$ . <sup>c</sup>The indicated value is based on a single determination at 50 mM methionine. <sup>d</sup>The indicated value is the average and standard deviation of 2 independent determinations at 50 mM methionine. <sup>e</sup>ND indicates values were not determined.

DMD #33639

**Table 3.** Steady-state kinetic parameters for FMO5 catalyzed oxygenation of 8-DPT.

Enzyme	$k_{cat}$ , min <sup>-1</sup>	$K_m$ , mM	$k_{cat}/K_m$ , min <sup>-1</sup> mM <sup>-1</sup>
MBP-FMO5	0.58 ± 0.03	0.12 ± 0.02	4.9 ± 0.8
Supersomal FMO5	1.01 ± 0.05 <sup>a</sup>	0.12 ± 0.02	8.4 ± 1.3 <sup>b</sup>

Kinetic assays were performed at 37°C, pH 8.5. Values are the fitting value and error from a single determination of 7 substrate concentrations ranging from 10 μM to 2 mM 8-DPT. <sup>a</sup>Comparison of this value to the MBP-FMO5 value yields  $p < 1 \times 10^{-4}$ .

<sup>b</sup>Comparison of this value to the MBP-FMO5 value yields  $p = 0.04$ .

Fig. 1




Figure 2




Figure 3






Figure 4




Figure 5




Figure 6




Figure 7

